Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
GLMD
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. (GLMD) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A); its weakest is Profitability (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.8
/ 5.0
C+
Value
B
Factor Score
3.2
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
C-
Factor Score
1.9
/ 5.0
Momentum
A
Factor Score
4.4
/ 5.0
Revisions
C-
Factor Score
2.1
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-4.5
EV / EBITDA
N/A
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
506.0%
Price Return 12M
86.9%
Catalyst Signal
0.00
Market Cap
$4.9M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-68.2%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-09-17 | B (3.2) | C+ (2.5) | C- (1.9) | A (4.4) | C- (2.1) | C+ (2.8) |
| 2026-09-10 | B- (3.1) | C+ (2.5) | C- (2.0) | C- (2.0) | C- (1.9) | C (2.3) |
| 2026-09-03 | B- (3.1) | C+ (2.5) | C- (2.0) | A+ (4.9) | C+ (2.5) | B- (3.0) |
| 2026-08-27 | B- (3.0) | C (2.4) | B- (2.9) | A+ (4.9) | C (2.3) | B- (3.1) |
| 2026-08-20 | B- (3.0) | C (2.4) | B- (2.9) | C- (2.0) | C (2.4) | C+ (2.5) |
Page
1
of
3